Home/Indications/Cardiovascular/Hypertension

Hypertension

Cardiovascular 2 original drugs

Novel Drugs

Reformulations

Drug Targets

Cardiovascular indication. Hypertension has 2 FDA-approved novel treatments, led by AstraZeneca, with 331 active industry clinical trials across 24 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Hypertension Market Leaders

Companies with the most FDA-approved novel Hypertension drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Combination Product: FDC of spironolactone and ER torsemide

Sarfez Pharmaceuticals, Inc.

Estimated · fresh NCT07223502

Q4 2026

TNX-103

Tenax Therapeutics, Inc.

Estimated · fresh NCT05983250

Q4 2026

HGP2102-1

Hanmi Pharmaceutical Company Limited

Estimated · stale NCT06174766

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Hypertension Treatments by Mechanism

Top 12 mechanisms across 68 industry trials with a known mechanism of action.

See full pipeline →

Calcium channel

2 trials 2 active 1 sponsor

Endothelin Receptor Antagonist

24 trials 1 active 5 sponsors

Angiotensin 2 Receptor Blocker

9 trials 1 active 7 sponsors

Prostacyclin Receptor Agonist

7 trials 1 active 1 sponsor

Atypical Antipsychotic

1 trials 1 active 1 sponsor

Thiazide-like Diuretic

6 trials 2 sponsors

AT1 receptor

5 trials 3 sponsors

Thiazide Diuretic

4 trials 3 sponsors

ETA/ETB

3 trials 1 sponsor

Dihydropyridine Calcium Channel Blocker

3 trials 1 sponsor

PDE5

2 trials 1 sponsor

Prostacycline

2 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Hypertension Clinical Pipeline by Phase

1022 industry-sponsored trials across 248 sponsors

View full landscape →

Showing 100 of 127 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Glaukos Corporation	—	—	RECRUITING	2026-08	NCT06848946
AOP Orphan Pharmaceuticals AG	Generic treprostinil sodium + Standard of Care (Double Oral)	—	RECRUITING	2027-06	NCT06317805
Shenzhen Ausa Pharmed Co.,Ltd	Amlodipine besylate	Calcium channel	RECRUITING	2029-06-30	NCT04974151
Shenzhen Ausa Pharmed Co.,Ltd	Amlodipine besylate	Calcium channel	RECRUITING	2030-06-30	NCT04974138
Chong Kun Dang Pharmaceutical	telmisartan	Angiotensin 2 Receptor Blocker [EPC]	RECRUITING	2025-10-31	NCT06431477
Genuine Research Center, Egypt	Nerkardou (5 mg) & (10 mg)	—	RECRUITING	2025-04-01	NCT05880056
United Therapeutics	Parenteral Treprostinil	—	ACTIVE NOT RECRUITING	2026-04-30	NCT05203510
Yuhan Corporation	Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg	—	ACTIVE NOT RECRUITING	2026-02-28	NCT06041529
Merck	Sotatercept	—	NOT YET RECRUITING	2028-04-03	NCT07600723
RECORDATI GROUP	Osilodrostat	—	NOT YET RECRUITING	2028-05	NCT07247162
Bayer	Adempas (Riociguat, BAY63-2521)	—	COMPLETED	2025-09-15	NCT02759419
Menarini International Operations Luxembourg SA	Nebivolol 5 mg	—	COMPLETED	2024-02-19	NCT06104423
Menarini International Operations Luxembourg SA	Nebivolol	—	COMPLETED	2022-11-15	NCT05513937
Hanmi Pharmaceutical Company Limited	Amlodipine 5mg	—	COMPLETED	2022-07-25	NCT03666351
United Therapeutics	Intravenous/Subcutaneous Treprostinil; Oral Treprostinil	—	COMPLETED	2022-05-11	NCT03497689
Menarini International Operations Luxembourg SA	Zofenopril	—	COMPLETED	2022-04-28	NCT05279807
Menarini International Operations Luxembourg SA	Zofenopril 30 mg	—	COMPLETED	2021-12-22	NCT05257148
Yuhan Corporation	Rosuampin 10/5mg	—	COMPLETED	2021-09-29	NCT03951207
Daewoong Pharmaceutical Co. LTD.	OLOMAX 20/5/5mg	—	COMPLETED	2021-07-06	NCT04120753
Yuhan Corporation	Duowell®	—	COMPLETED	2020-09-02	NCT03267329
Actelion	Selexipag	Prostacyclin Receptor Agonist [EPC]	COMPLETED	2020-02-10	NCT03078907
Bayer	Riociguat (Adempas, BAY63-2521)	—	COMPLETED	2020-01-29	NCT02891850
Chong Kun Dang Pharmaceutical	Cantabell Tab	—	COMPLETED	2020-01-28	NCT04521023
KRKA	Amlessa®	—	COMPLETED	2019-09-27	NCT03738761
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2019-09-10	NCT02310672
Yuhan Corporation	Duowell®	—	COMPLETED	2019-06-07	NCT03474562
Sumitomo Pharma (Suzhou) Co., Ltd.	Arotinolol Hydrochloride	—	COMPLETED	2018-09-13	NCT02612298
Chong Kun Dang Pharmaceutical	Telminuvo®Tab. 40/2.5mg	—	COMPLETED	2018-03	NCT02231788
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2017-10-25	NCT02382016
Boryung Pharmaceutical Co., Ltd	Fimasartan	—	COMPLETED	2017-05	NCT02495324
Neutec Ar-Ge San ve Tic A.Ş	S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet	—	COMPLETED	2017-02-14	NCT03038451
Takeda	Azilsartan Medoxomil	—	COMPLETED	2016-11-15	NCT02517866
Dong-A ST Co., Ltd.	OROSARTAN® 5/160mg	—	COMPLETED	2016-09-08	NCT02433119
Bayer	Nifedipine (Adalat GITS, BAY1040)	—	COMPLETED	2016-08-08	NCT02413515
Bayer	Riociguat (Adempas, BAY63-2521)	—	COMPLETED	2016-07-16	NCT02191137
Boryung Pharmaceutical Co., Ltd	Fimasartan	—	COMPLETED	2016-06	NCT01736488
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Sildenafil	—	COMPLETED	2016-05-20	NCT01642407
Novartis	amlodipine/valsartan	—	COMPLETED	2015-09	NCT02062645
Janssen Scientific Affairs, LLC	Canagliflozin	SGLT2	COMPLETED	2015-04	NCT01939496
Chong Kun Dang Pharmaceutical	Candemore tablet	—	COMPLETED	2014-10	NCT01682564
Shanghai Shyndec Pharmaceutical Co., Ltd.	nifedipine CR tablets (Xin Ran)	—	COMPLETED	2014-07	NCT02031861
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2014-04	NCT01508325
United Therapeutics	Remodulin	—	COMPLETED	2014-03	NCT02847260
TSH Biopharm Corporation Limited	Amlodipine/Valsartan	—	COMPLETED	2014-03	NCT02058446
Lee's Pharmaceutical Limited	Aspirine	—	COMPLETED	2014-03	NCT02594410
Astellas	Perdipine injection	—	COMPLETED	2014-01	NCT01872039
Shenzhen Ausa Pharmed Co.,Ltd	Enalapril/folic acid	—	COMPLETED	2013-08	NCT00794885
Organon and Co	Losartan (+) amlodipine	—	COMPLETED	2013-04-22	NCT01277822
Novartis	Aliskiren	—	COMPLETED	2013-04	NCT01176032
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2013-04	NCT01066039
Lee's Pharmaceutical Limited	Zanidip	—	COMPLETED	2013-03	NCT01520285
Novartis	Valsartan	Angiotensin 2 Receptor Blocker [EPC]	COMPLETED	2013-01	NCT01541189
Hanmi Pharmaceutical Company Limited	Amosartan® tab	—	COMPLETED	2013-01	NCT01828359
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	Perindopril + amlodipine + if necessary, hydrochlorothiazide	—	COMPLETED	2012-11	NCT01101009
Novartis	Aliskiren	—	COMPLETED	2012-11	NCT01570686
GSK	current marketed FLOLAN (epoprostenol sodium)	—	COMPLETED	2012-05-16	NCT01462565
Forest Laboratories	Nebivolol	—	COMPLETED	2012-03	NCT01415531
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Caduet	Calcium channels/HMGCR	COMPLETED	2012-02	NCT01190007
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2012-02	NCT01251146
Bayer	Nifedipine (Adalat, BAYA1040) and Valsartan	—	COMPLETED	2012-02	NCT01071122
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2011-12	NCT01190436
Novartis	Aliskiren and HCTZ	—	COMPLETED	2011-10	NCT01056731
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2011-10	NCT01079962
Novartis	Aliskiren	—	COMPLETED	2011-10	NCT00927394
Novartis	Valsartan and hydrochlorothiazide (HCTZ) - monotherapy	—	COMPLETED	2011-07	NCT00902304
Actelion	ACT-385781A (Actelion Epoprostenol)	—	COMPLETED	2011-07	NCT01105117
Actelion	ACT-385781A (Actelion Epoprostenol)	—	COMPLETED	2011-05	NCT01105091
Bayer	Adalat (Nifedipine, BAYA1040)	—	COMPLETED	2011-05	NCT00993109
Forest Laboratories	nebivolol and lisinopril (free combination)	—	COMPLETED	2011-05	NCT01218100
Novartis	Valsartan/Amlodipine	—	COMPLETED	2011-04	NCT01167153
Jiangsu Simcere Pharmaceutical Co., Ltd.	Levamlodipine besylate	—	COMPLETED	2011-03	NCT01131546
Gilead	Ambrisentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2011-02	NCT00617305
Novartis	valsartan/amlodipine	—	COMPLETED	2011-01	NCT01241487
Novartis	Aliskiren	—	COMPLETED	2011-01	NCT01042392
Forest Laboratories	Nebivolol	—	COMPLETED	2010-12	NCT01057251
Novartis	Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)	—	COMPLETED	2010-10	NCT01070030
Novartis	Amlodipine 5mg/Valsartan 80 mg	—	COMPLETED	2010-09	NCT01070043
LaborMed Pharma S.A.	Hydrochlorothiazide	Thiazide Diuretic [EPC]	COMPLETED	2010-08	NCT00980187
Forest Laboratories	Nebivolol with concomitant losartan or lisinopril	—	COMPLETED	2010-07-09	NCT00673790
GE Healthcare	Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)	—	COMPLETED	2010-07	NCT00878878
Forest Laboratories	Nebivolol	—	COMPLETED	2010-07	NCT00744237
Novartis	Aliskiren	—	COMPLETED	2010-06	NCT00865020
Takeda	Candesartan cilexetil and hydrochlorothiazide	Thiazide Diuretic [EPC]	COMPLETED	2010-05	NCT01012479
Boehringer Ingelheim	Telmisartan	Angiotensin 2 Receptor Blocker [EPC]	COMPLETED	2010-04	NCT00926289
United Therapeutics	Inhaled treprostinil	—	COMPLETED	2010-03	NCT00741819
Novartis	Aliskiren/Amlodipine	—	COMPLETED	2010-03	NCT00942994
Forest Laboratories	nebivolol	—	COMPLETED	2010-03	NCT00734630
Novartis	Amlodipine	—	COMPLETED	2010-01	NCT00787605
Daiichi Sankyo	olmesartan medoxomil	AT1 receptor	COMPLETED	2010-01	NCT00949884
Novartis	valsartan, amlodipine, HCTZ	—	COMPLETED	2010-01	NCT00931710
Novartis	Aliskiren	—	COMPLETED	2009-12	NCT00797316
Forest Laboratories	Nebivolol	—	COMPLETED	2009-11	NCT00770861
Organon and Co	losartan potassium	AT1 receptor	COMPLETED	2009-09-01	NCT00496834
Novartis	Aliskiren	—	COMPLETED	2009-09	NCT00631917
Forest Laboratories	Nebivolol	—	COMPLETED	2009-09	NCT00673075
Sanofi	Ramipril + Felodipine	—	COMPLETED	2009-09	NCT00841880
Novartis	Aliskiren	—	COMPLETED	2009-08	NCT00765947
Daiichi Sankyo	amlodipine and olmesartan medoxomil tablets	—	COMPLETED	2009-08	NCT00791258
Novartis	Aliskiren/Amlodipine	—	COMPLETED	2009-08	NCT00853957
Forest Laboratories	Nebivolol	—	COMPLETED	2009-08	NCT00785512

Showing 100 of 371 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Tenax Therapeutics, Inc.	TNX-103	—	RECRUITING	2026-10	NCT05983250
Hanmi Pharmaceutical Company Limited	HGP2102-1	—	RECRUITING	2026-12-31	NCT06174766
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	RECRUITING	2027-01-31	NCT05179876
YS Life Science Co., Ltd.	Bimatoprost ophthalmic solution 0.01% YSBP	—	RECRUITING	2027-11-01	NCT07661329
Tenax Therapeutics, Inc.	TNX-103	—	RECRUITING	2028-06-30	NCT07288398
AOP Orphan Pharmaceuticals AG	preservative-free parenteral treprostinil	—	RECRUITING	2028-11	NCT06350032
Hanlim Pharm. Co., Ltd.	Test group	—	RECRUITING	2028-12	NCT07552389
Merck	Sotatercept	—	RECRUITING	2028-12-07	NCT07218029
Insmed Incorporated	Treprostinil Palmitil Inhalation Powder	—	RECRUITING	2028-12-28	NCT07481981
Insmed Incorporated	Treprostinil Palmitil Inhalation Powder	—	RECRUITING	2028-12-30	NCT07179380
Inhibikase Therapeutics	IKT-001	—	RECRUITING	2029-06	NCT07365332
Liquidia Technologies, Inc.	L606	—	RECRUITING	2029-07	NCT07285655
Boehringer Ingelheim	Vicadrostat	—	RECRUITING	2029-12-14	NCT07064473
AstraZeneca	Baxdrostat/dapagliflozin	—	RECRUITING	2029-12-18	NCT06742723
Alnylam Pharmaceuticals	Zilebesiran	—	RECRUITING	2030-09-30	NCT07181109
Qlaris Bio, Inc.	Latanoprost (0.005%)	—	RECRUITING	2026-07-01	NCT07354516
Sarfez Pharmaceuticals, Inc.	Combination Product: FDC of spironolactone and ER torsemide	—	RECRUITING	2026-07	NCT07223502
THPharm Corp.	THP-00101	—	RECRUITING	2026-06-01	NCT06647745
JW Pharmaceutical	JW0104+C2402	—	RECRUITING	2026-04	NCT06643130
Chong Kun Dang Pharmaceutical	Sacubitril∙Valsartan(dose maintenance)	—	RECRUITING	2026-03-31	NCT06643819
Addpharma Inc.	AD-227A	—	RECRUITING	2025-09	NCT06441630
Pulnovo Medical (Wuxi) Co., Ltd.	Guideline-directed medical therapy (GDMT) for heart failure	—	RECRUITING	2025-08	NCT05824923
Addpharma Inc.	AD-224A	—	RECRUITING	2025-07	NCT06291207
Boryung Pharmaceutical Co., Ltd	BR1019A	—	RECRUITING	2025-04	NCT06220773
Addpharma Inc.	AD-209	—	RECRUITING	2025-02	NCT06348576
AJU Pharm Co., Ltd.	AJU-C52L, AJU-C52	—	RECRUITING	2022-12-12	NCT06416865
GB002, Inc.	Seralutinib	—	ACTIVE NOT RECRUITING	2026-12	NCT06274801
Insmed Incorporated	Treprostinil Palmitil	—	ACTIVE NOT RECRUITING	2026-12-31	NCT05649748
Eli Lilly	Orforglipron	—	ACTIVE NOT RECRUITING	2027-09	NCT06948422
Eli Lilly	Orforglipron	—	ACTIVE NOT RECRUITING	2027-09	NCT06952530
Eli Lilly	Orforglipron	—	ACTIVE NOT RECRUITING	2027-09	NCT06948435
AstraZeneca	Baxdrostat/dapagliflozin	—	ACTIVE NOT RECRUITING	2028-02-24	NCT06268873
Mineralys Therapeutics Inc.	lorundrostat	—	ACTIVE NOT RECRUITING	2025-12-30	NCT05968430
Actelion	Macitentan 10 mg	—	ACTIVE NOT RECRUITING	2025-10-07	NCT04273945
Liquidia Technologies, Inc.	LIQ861 Inhaled Treprostinil	—	ACTIVE NOT RECRUITING	2025-05-31	NCT03992755
Liquidia Technologies, Inc.	—	—	ACTIVE NOT RECRUITING	2025-03-20	NCT04691154
Actelion	Selexipag	Prostacyclin Receptor Agonist [EPC]	ACTIVE NOT RECRUITING	2024-10-11	NCT04175600
Ablative Solutions, Inc.	Dehydrated alcohol	—	ACTIVE NOT RECRUITING	2023-12	NCT02910414
Bayer	Riociguat (Adempas, BAY63-2521)	—	ACTIVE NOT RECRUITING	2020-03-07	NCT02562235
Hanmi Pharmaceutical Company Limited	HCP1803-3	—	NOT YET RECRUITING	2027-10-30	NCT07660796
Zentiva, k.s.	Amlodipine	—	NOT YET RECRUITING	2027-12-31	NCT07618806
Eurofarma Laboratorios S.A.	N0877	—	NOT YET RECRUITING	2028-04-30	NCT06608472
VIVUS LLC	VI-0106	—	NOT YET RECRUITING	2028-05-31	NCT07612657
EMS	TCA108	—	NOT YET RECRUITING	2029-05	NCT07030101
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Aprocitentan tablets(SYH9108)	—	NOT YET RECRUITING	2029-12-28	NCT07635914
Inhibikase Therapeutics	IKT-001	—	NOT YET RECRUITING	2030-06-30	NCT07632898
Insmed Incorporated	Treprostinil Palmitil Inhalation Powder	—	NOT YET RECRUITING	2031-01-22	NCT07234032
Wuhan Createrna Science and Technology Co., Ltd	QR12000 75mg	—	NOT YET RECRUITING	2026-04-30	NCT06716970
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	SYH9056	—	NOT YET RECRUITING	2026-03-30	NCT06771245
Insmed Incorporated	Treprostinil Palmitil Inhalation Powder	—	COMPLETED	2026-04-01	NCT05649722
Daewoong Pharmaceutical Co. LTD.	DWC202405	—	COMPLETED	2026-02-05	NCT06671392
United Therapeutics	Ralinepag	—	COMPLETED	2025-12-31	NCT03626688
GB002, Inc.	Seralutinib	—	COMPLETED	2025-11-27	NCT05934526
AstraZeneca	Baxdrostat	—	COMPLETED	2025-11-24	NCT06344104
Boryung Pharmaceutical Co., Ltd	BR1018A	—	COMPLETED	2025-11-11	NCT06165250
Daewoong Pharmaceutical Co. LTD.	DWC202404, DWC202314	—	COMPLETED	2025-10-02	NCT06682000
AstraZeneca	Baxdrostat	—	COMPLETED	2025-08-17	NCT06168409
Ahn-Gook Pharmaceuticals Co.,Ltd	AGSAVI	—	COMPLETED	2025-06-10	NCT05503953
Novartis	LCZ	—	COMPLETED	2025-05-28	NCT06236061
AstraZeneca	Baxdrostat	—	COMPLETED	2025-05-21	NCT06034743
Laboratorios Richmond S.A.C.I.F.	Treatment with nifedipine	—	COMPLETED	2025-04-15	NCT07448506
Addpharma Inc.	AD-223A	—	COMPLETED	2025-03-27	NCT06052748
Mineralys Therapeutics Inc.	lorundrostat Dose 1	—	COMPLETED	2024-12-10	NCT06153693
Hanmi Pharmaceutical Company Limited	HCP1803-3	—	COMPLETED	2024-12-02	NCT06438172
Boryung Pharmaceutical Co., Ltd	Fimasartan + Indapamide	—	COMPLETED	2024-12-02	NCT05878561
Otsuka Beijing Research Institute	OPC-1085EL	—	COMPLETED	2024-11-22	NCT05583474
Daewoong Pharmaceutical Co. LTD.	(D) DWC202206	—	COMPLETED	2024-09-10	NCT05643508
Boryung Pharmaceutical Co., Ltd	Fimasartan	—	COMPLETED	2024-09-05	NCT05930028
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2024-08-28	NCT02932410
Janssen Pharmaceutical K.K.	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2024-08-23	NCT05167825
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Sotatercept	—	COMPLETED	2024-07-26	NCT04896008
Celltrion	AZM X mg + AML Y mg	—	COMPLETED	2024-07-11	NCT05385770
Kyungdong Pharmaceutical Co., Ltd.	KDF1901-R0	—	COMPLETED	2024-06-20	NCT07116863
Chong Kun Dang Pharmaceutical	D064, D702, placebo of D660	—	COMPLETED	2024-05-13	NCT05931224
Chong Kun Dang Pharmaceutical	D064 and D702, QD	—	COMPLETED	2024-03-22	NCT06121518
Merck	Sotatercept	—	COMPLETED	2024-03-12	NCT05818137
Celltrion Pharm, Inc.	Amlodipine	—	COMPLETED	2024-02-13	NCT07564726
Santen Pharmaceutical Co., Ltd.	STN1012600 ophthalmic solution 0.002%	—	COMPLETED	2024-01-30	NCT05503901
Merck	Frespaciguat	—	COMPLETED	2024-01-04	NCT04732221
Takeda	TAK-536	—	COMPLETED	2023-12-28	NCT04668157
Actelion	macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2023-12-27	NCT03422328
Shanghai Pharmaceuticals Holding Co., Ltd	SPH3127 tablet	—	COMPLETED	2023-12-26	NCT05359068
Hanmi Pharmaceutical Company Limited	HCP2102-1	—	COMPLETED	2023-12-11	NCT05450601
Shenzhen Salubris Pharmaceuticals Co., Ltd.	Allisartan Isoproxil/Sustained-Release Indapamide	—	COMPLETED	2023-11-27	NCT06500689
Actelion	Selexipag	Prostacyclin Receptor Agonist [EPC]	COMPLETED	2023-11-10	NCT04565990
George Medicines PTY Limited	Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg	—	COMPLETED	2023-09-19	NCT04518306
Laboratorios Silanes S.A. de C.V.	Losartan/Chlorthalidone in fixed dose	—	COMPLETED	2023-08-15	NCT04927299
George Medicines PTY Limited	Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg	—	COMPLETED	2023-08-11	NCT04518293
Hanmi Pharmaceutical Company Limited	HCP1803-3	—	COMPLETED	2023-06-05	NCT05362110
Santen Pharmaceutical Co., Ltd.	STN1012600 ophthalmic solution 0.002%	—	COMPLETED	2023-04-18	NCT05495061
Laboratoires Thea	—	—	COMPLETED	2023-04-13	NCT04898387
Santen Pharmaceutical Co., Ltd.	A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL	—	COMPLETED	2023-04-04	NCT03822559
Handok Inc.	Irbesartan/Amlodipine low	—	COMPLETED	2023-04-03	NCT05476354
Handok Inc.	Irbesartan/Amlodipine	—	COMPLETED	2023-03-30	NCT05475665
JW Pharmaceutical	LivaloVA	—	COMPLETED	2022-11-08	NCT05331014
Hanmi Pharmaceutical Company Limited	HCP1904-3	—	COMPLETED	2022-09-14	NCT05199129
Quantum Genomics SA	Firibastat	—	COMPLETED	2022-08-30	NCT04277884
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Sotatercept	—	COMPLETED	2022-08-26	NCT04576988
Actelion	FDC macitentan/tadalafil	—	COMPLETED	2022-08-23	NCT03904693
Shenzhen Salubris Pharmaceuticals Co., Ltd.	Allisartan Isoproxil/Amlodipine group 1	—	COMPLETED	2022-08-16	NCT06465264

Showing 100 of 256 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Retension Pharmaceuticals. Inc.	RTN-001	—	RECRUITING	2026-10	NCT07142356
Vanda Pharmaceuticals	iloperidone	Atypical Antipsychotic [EPC]	RECRUITING	2026-10	NCT07090161
Tectonic Therapeutic	TX000045- Dose A	—	RECRUITING	2026-10-09	NCT06616974
Pulmovant, Inc.	inhaled mosliciguat	—	RECRUITING	2026-12	NCT07333183
Kardigan, Inc.	Tonlamarsen	—	RECRUITING	2026-12-29	NCT07511361
AllRock Bio, Inc.	ROC-101	—	RECRUITING	2027-03	NCT07175038
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL0140	—	RECRUITING	2027-03-01	NCT07654140
AstraZeneca	Baxdrostat/dapagliflozin	—	RECRUITING	2027-05-24	NCT07222917
Apollo Therapeutics Ltd	APL-9796	—	RECRUITING	2027-08-30	NCT06846554
Regeneron	REGN13335	—	RECRUITING	2028-02-27	NCT07318597
Alnylam Pharmaceuticals	ALN-AGT01 RVR	—	RECRUITING	2028-04-01	NCT07553442
Foresee Pharmaceuticals Co., Ltd.	Mirivadelgat	—	RECRUITING	2028-06	NCT06475781
Pfizer	PF-07868489	—	RECRUITING	2028-07-18	NCT07073820
Merck	Sotatercept	—	RECRUITING	2028-09-21	NCT05587712
Novartis	LTP	—	RECRUITING	2028-11-29	NCT06649110
Novartis	QCZ484	—	RECRUITING	2031-05-31	NCT07543120
E-Star BioTech, LLC	MANP	—	RECRUITING	2026-07-01	NCT06343298
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-9563 Injection	—	RECRUITING	2026-07	NCT07297797
Shin Poong Pharmaceutical Co. Ltd.	SPC 1001 Mid2	—	RECRUITING	2025-10-08	NCT06826872
Pfizer	PF-07868489	—	ACTIVE NOT RECRUITING	2026-09-02	NCT06137742
Pulmovant, Inc.	Mosliciguat	—	ACTIVE NOT RECRUITING	2026-12	NCT06635850
Novartis	QCZ484	—	ACTIVE NOT RECRUITING	2027-01-29	NCT06857955
OrphAI Therapeutics	LAM-001	—	ACTIVE NOT RECRUITING	2027-07-16	NCT05798923
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	GB002 (seralutinib)	—	ACTIVE NOT RECRUITING	2027-12	NCT04816604
Merck	Sotatercept	—	ACTIVE NOT RECRUITING	2028-06-16	NCT06925750
Merck	Sotatercept	—	ACTIVE NOT RECRUITING	2035-08-10	NCT06814145
Merck	Frespaciguat	—	ACTIVE NOT RECRUITING	2026-04-09	NCT05612035
Actelion	selexipag (Uptravi)	—	ACTIVE NOT RECRUITING	2022-03-28	NCT03492177
Vincentage Pharma Co., Ltd	VCT220 Tablet	—	NOT YET RECRUITING	2026-10-20	NCT07360275
Boryung Pharmaceutical Co., Ltd	BR1400-1	—	NOT YET RECRUITING	2027-02-01	NCT07373613
NuSirt Biopharma	NS-0200 (low sildenafil)	—	NOT YET RECRUITING	2027-05-02	NCT07647003
Tectonic Operating Company, Inc.	TX000045	—	NOT YET RECRUITING	2027-11-21	NCT07473700
Diagonal Therapeutics, Inc.	DIAG723	—	NOT YET RECRUITING	2027-11-30	NCT07623525
NS Pharma, Inc.	NS-863 Low Dose	—	NOT YET RECRUITING	2028-08-01	NCT07441200
NS Pharma, Inc.	NS-863 Low Dose	—	NOT YET RECRUITING	2028-09-14	NCT07441278
ARKAY Therapeutics	Metformin	—	NOT YET RECRUITING	2028-11-26	NCT03686657
BeBetter Med Inc	BEBT-701 Injection	—	NOT YET RECRUITING	2028-11-30	NCT07368608
Innovent Biologics (Suzhou) Co. Ltd.	IBI3016	—	NOT YET RECRUITING	2029-03-27	NCT07352969
Merck	Sotatercept	—	NOT YET RECRUITING	2029-05-24	NCT07646860
Kardigan, Inc.	Tonlamarsen	—	COMPLETED	2026-01-12	NCT06864104
Mineralys Therapeutics Inc.	Lorundrostat	—	COMPLETED	2025-12-17	NCT06785454
Merck	Sotatercept	—	COMPLETED	2025-11-20	NCT06664801
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Sotatercept 0.3 mg/kg	—	COMPLETED	2025-09-05	NCT04945460
Alnylam Pharmaceuticals	Zilebesiran	—	COMPLETED	2025-07-17	NCT06423352
AstraZeneca	AZD3427	—	COMPLETED	2025-07-15	NCT05737940
Bayer	Riociguat (Adempas, BAY63-2521).	—	COMPLETED	2025-07-03	NCT00694850
Alnylam Pharmaceuticals	Zilebesiran	—	COMPLETED	2025-06-19	NCT06272487
Insmed Incorporated	Treprostinil Palmitil	—	COMPLETED	2025-03-27	NCT05147805
Keros Therapeutics, Inc.	Dose A KER-012	—	COMPLETED	2025-03-05	NCT05975905
Mineralys Therapeutics Inc.	lorundrostat Dose 1	—	COMPLETED	2025-01-15	NCT05769608
Qlaris Bio, Inc.	QLS-111, 0.015%	—	COMPLETED	2024-12-20	NCT06249152
AstraZeneca	Baxdrostat	—	COMPLETED	2024-12-04	NCT06336356
Respira Therapeutics, Inc.	—	—	COMPLETED	2024-11-20	NCT04266197
Qlaris Bio, Inc.	Experimental: QLS-111 ophthalmic solution, (0.015%)	—	COMPLETED	2024-08-20	NCT06016972
Cereno Scientific AB	CS1 Administration	—	COMPLETED	2024-08-01	NCT05224531
Novartis	XXB750 drug	—	COMPLETED	2024-07-02	NCT05562934
AstraZeneca	CIN-107	—	COMPLETED	2024-05-02	NCT05432167
Insmed Incorporated	Treprostinil Palmitil	—	COMPLETED	2024-03-14	NCT05176951
Alnylam Pharmaceuticals	Indapamide	Thiazide-like Diuretic [EPC]	COMPLETED	2023-12-11	NCT05103332
Addpharma Inc.	AD-209	—	COMPLETED	2023-11-27	NCT05631990
AstraZeneca	CIN-107	—	COMPLETED	2023-11-07	NCT05459688
BackBeat Medical Inc	—	—	COMPLETED	2023-08-11	NCT05086523
Altavant Sciences GmbH	rodatristat ethyl 300 mg tablet BID	—	COMPLETED	2023-06-05	NCT04712669
Alnylam Pharmaceuticals	ALN-AGT01	—	COMPLETED	2023-04-04	NCT04936035
Ionis Pharmaceuticals, Inc.	ION904	—	COMPLETED	2023-01-31	NCT05314439
Apnimed	AD113	—	COMPLETED	2023-01-31	NCT04905979
Shin Poong Pharmaceutical Co. Ltd.	SPC1001 High	—	COMPLETED	2022-11-27	NCT06212648
Shanghai Pharmaceuticals Holding Co., Ltd	SPH3127	—	COMPLETED	2022-10-24	NCT05593562
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	GB002 (seralutinib)	—	COMPLETED	2022-10-17	NCT04456998
CinCor Pharma, Inc.	CIN-107	—	COMPLETED	2022-09-13	NCT05137002
Mineralys Therapeutics Inc.	MLS-101 (Part I)	—	COMPLETED	2022-09-07	NCT05001945
Ionis Pharmaceuticals, Inc.	IONIS-AGT-LRx	—	COMPLETED	2022-06-29	NCT04714320
Vigonvita Life Sciences	TPN171H	—	COMPLETED	2022-06-29	NCT04483115
CinCor Pharma, Inc.	CIN-107	—	COMPLETED	2022-06-14	NCT04519658
GSK	Ambrisentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2022-06-09	NCT01342952
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2022-03-21	NCT02060721
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Sotatercept	—	COMPLETED	2022-03-09	NCT03496207
Hanmi Pharmaceutical Company Limited	HCP1803-3	—	COMPLETED	2022-02-28	NCT04959305
Bial - Portela C S.A.	Oral zamicastat	—	COMPLETED	2022-02-17	NCT06009185
Ablative Solutions, Inc.	Alcohol	—	COMPLETED	2022-01-31	NCT03503773
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Sotatercept	—	COMPLETED	2021-12-21	NCT03738150
Handok Inc.	Irbesartan/Amlodipine	—	COMPLETED	2021-11-09	NCT04488978
Bial - Portela C S.A.	Oral zamicastat	—	COMPLETED	2021-10-20	NCT04316143
Bellerophon	—	—	COMPLETED	2021-09-07	NCT03727451
United Therapeutics	Ralinepag	—	COMPLETED	2021-03-29	NCT02279745
Addpharma Inc.	AD209	—	COMPLETED	2021-02-25	NCT04218552
KBP Biosciences	KBP-5074 0.25 mg tablet	—	COMPLETED	2020-08-05	NCT03574363
Ionis Pharmaceuticals, Inc.	ISIS 757456	—	COMPLETED	2020-07-20	NCT04083222
Shanghai Pharmaceuticals Holding Co., Ltd	SPH3127 tablet Dose 1	—	COMPLETED	2020-06-30	NCT03756103
Tenax Therapeutics, Inc.	Levosimendan	—	COMPLETED	2020-04-07	NCT03541603
Actelion	Macitentan 10mg	—	COMPLETED	2020-03-13	NCT02554903
Hanmi Pharmaceutical Company Limited	HCP1803	—	COMPLETED	2020-02-26	NCT03897868
Respira Therapeutics, Inc.	—	—	COMPLETED	2020-01-17	NCT05343637
Ionis Pharmaceuticals, Inc.	ISIS 757456	—	COMPLETED	2019-11-13	NCT03714776
Nicox Ophthalmics, Inc.	NCX 470	—	COMPLETED	2019-08-23	NCT03657797
Santen Inc.	DE-117 Ophthalmic Solution QD	—	COMPLETED	2019-06-20	NCT03858894
LongStar HealthPro, Inc. DBA Farlong Pharmaceutical	—	—	COMPLETED	2019-06-01	NCT04069715
GSK	GSK2586881	—	COMPLETED	2019-05-07	NCT03177603
Aerogen Pharma Limited	—	—	COMPLETED	2019-03-01	NCT03122730
Envisia Therapeutics	ENV515-3 Travoprost XR	—	COMPLETED	2019-02-13	NCT02371746

Showing 100 of 268 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Eli Lilly	LY3971297	—	RECRUITING	2026-08	NCT06148272
Suzhou Alphamab Co., Ltd.	KN060	—	RECRUITING	2026-12-30	NCT07191899
Kyowa Kirin Co., Ltd.	KK3910	—	RECRUITING	2027-12	NCT06823947
Beijing Continent Pharmaceutical Co, Ltd.	F230 tablets	—	RECRUITING	2026-07-01	NCT06899815
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	VB19055	—	RECRUITING	2026-07	NCT07254481
Pharmosa Biopharm Inc.	L608 Liposomal inhalation suspension	—	RECRUITING	2026-06-30	NCT06429930
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL0140	—	RECRUITING	2026-01	NCT07051603
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-9563, placebo	—	RECRUITING	2025-12	NCT07117474
Bichedam Co., Ltd.	BCD101 Low Dose Liquid Formulation	—	RECRUITING	2025-09-23	NCT07282145
Neurotronic, Inc.	—	—	RECRUITING	2025-01	NCT05369065
Neurotronic, Inc.	—	—	RECRUITING	2025-01	NCT05363761
ADARx Pharmaceuticals, Inc.	ADX-850	—	ACTIVE NOT RECRUITING	2026-07-31	NCT06205628
Arnatar Therapeutics, Inc.	ART101 injection	—	ACTIVE NOT RECRUITING	2026-10-14	NCT07614308
PolyActiva Pty Ltd	—	—	ACTIVE NOT RECRUITING	2027-02-15	NCT06964061
Huons Co., Ltd.	HUC2-565-A, HUC2-565-A and HUC2-565-B	—	ACTIVE NOT RECRUITING	2024-07-12	NCT06618079
Autotelicbio	ATB-U101	—	NOT YET RECRUITING	2026-07-31	NCT07590466
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10522	—	NOT YET RECRUITING	2027-01-20	NCT07609875
Novartis	HJB647	—	NOT YET RECRUITING	2027-01-20	NCT07644364
35Pharma Inc	HS235	—	NOT YET RECRUITING	2027-04	NCT07143448
35Pharma Inc	HS235	—	NOT YET RECRUITING	2027-09	NCT07123779
Innovent Biologics (Suzhou) Co. Ltd.	IBI3016	—	NOT YET RECRUITING	2027-10-16	NCT07556796
Addpharma Inc.	AD-231	—	NOT YET RECRUITING	2026-07	NCT07590167
Boryung Pharmaceutical Co., Ltd	BR1015-A	—	NOT YET RECRUITING	2026-06-17	NCT07421414
Boryung Pharmaceutical Co., Ltd	BR1015-A	—	NOT YET RECRUITING	2026-06-11	NCT07421401
Boryung Pharmaceutical Co., Ltd	BR1015-A	—	NOT YET RECRUITING	2026-06-07	NCT07421388
Boryung Pharmaceutical Co., Ltd	BR1015-A	—	NOT YET RECRUITING	2026-05-31	NCT07421375
Qilu Pharmaceutical Co., Ltd.	QLS1410 (CYP11B2 inhibitor)	—	NOT YET RECRUITING	2026-05	NCT07152444
Shenzhen Salubris Pharmaceuticals Co., Ltd.	Sequence A T-R-T-R	—	NOT YET RECRUITING	2026-04-25	NCT07486453
Guangzhou Magpie Pharmaceuticals Co., Ltd.	MN-08 24 mg/day	—	NOT YET RECRUITING	2026-03-30	NCT05660863
Addpharma Inc.	Treatment A(AD-2321)	—	NOT YET RECRUITING	2026-02-11	NCT07312799
Qilu Pharmaceutical Co., Ltd.	QLS1410	—	NOT YET RECRUITING	2026-02-07	NCT07358858
Addpharma Inc.	Treatment A(AD-231A)	—	NOT YET RECRUITING	2026-02-07	NCT07312773
Gedeon Richter Plc.	Azilsartan medoxomil 80 mg tablet	—	NOT YET RECRUITING	2025-07-01	NCT06990204
Arnatar Therapeutics, Inc.	Subcutaneous (SC) single dose	—	COMPLETED	2025-12-19	NCT07529600
Bayer	BAY3283142	—	COMPLETED	2025-11-21	NCT06428825
Addpharma Inc.	Co-administration of AD-227A and AD-227B	—	COMPLETED	2025-08-13	NCT06884085
Boryung Pharmaceutical Co., Ltd	BR1018	—	COMPLETED	2025-07-23	NCT06889012
Bayer	BAY2701250 IV	—	COMPLETED	2025-05-20	NCT06048120
Suzhou Sanegene Bio Inc.	SGB-3908	—	COMPLETED	2025-04-07	NCT06501586
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2025-03-19	NCT06744062
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2025-03-16	NCT06744439
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2025-03-14	NCT06744127
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2025-03-12	NCT06744426
Humanis Saglık Anonim Sirketi	Selexipag Film Coated Tablets	—	COMPLETED	2025-03-03	NCT06932198
Boryung Pharmaceutical Co., Ltd	BR1019	—	COMPLETED	2024-12-11	NCT06636877
Hanlim Pharm. Co., Ltd.	Test group 1	—	COMPLETED	2024-11-15	NCT07568652
Boryung Pharmaceutical Co., Ltd	BR1400-1	—	COMPLETED	2024-10-08	NCT06889064
Novartis	QCZ484	—	COMPLETED	2024-09-25	NCT06905327
Pharmosa Biopharm Inc.	L608 Inhalation Solution	—	COMPLETED	2024-09-02	NCT05938946
Humanis Saglık Anonim Sirketi	Bosentan Dispersible Tablets	—	COMPLETED	2024-05-22	NCT06484673
Chong Kun Dang Pharmaceutical	CKD-341, D956	—	COMPLETED	2024-05-07	NCT06281132
Boryung Pharmaceutical Co., Ltd	BR1019	—	COMPLETED	2024-03-31	NCT06226727
Chong Kun Dang Pharmaceutical	CKD-348(6)	—	COMPLETED	2024-02-19	NCT06112678
Boryung Pharmaceutical Co., Ltd	BR1017-1	—	COMPLETED	2024-02-18	NCT06184269
Actelion	Prostacyclin Receptor Agonist	—	COMPLETED	2023-12-05	NCT05427162
THPharm Corp.	THP-00101 (Dapagliflozin) 10mg	—	COMPLETED	2023-11-09	NCT06063109
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2023-10-06	NCT06008028
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2023-10-03	NCT06008015
Chong Kun Dang Pharmaceutical	CKD-828, D064, D702	—	COMPLETED	2023-09-02	NCT05881707
Chong Kun Dang Pharmaceutical	CKD-341, D958	—	COMPLETED	2023-09-01	NCT05921435
United Therapeutics	Treprostinil Inhalation Powder	—	COMPLETED	2023-08-22	NCT03950739
Chong Kun Dang Pharmaceutical	CKD-828, D064, D701	—	COMPLETED	2023-07-18	NCT05834595
Hanlim Pharm. Co., Ltd.	Test group 1	—	COMPLETED	2023-07-12	NCT07598968
Boryung Pharmaceutical Co., Ltd	BR1019-1	—	COMPLETED	2023-06-29	NCT05875259
Vicore Pharma AB	C106 solution	—	COMPLETED	2023-06-22	NCT05427253
Celltrion	L04RD1	—	COMPLETED	2023-06-12	NCT05993806
Brillian Pharma Inc.	Amlodipine Freeze-Dried Powder for Oral Solution 5 mg	—	COMPLETED	2023-04-17	NCT05808725
Humanis Saglık Anonim Sirketi	Riociguat film coated tablets	—	COMPLETED	2023-03-17	NCT06180096
Bayer	BAY3283142	—	COMPLETED	2023-01-03	NCT05491642
Chong Kun Dang Pharmaceutical	CKD-341	—	COMPLETED	2022-12-04	NCT05571813
Aerami Therapeutics	AER-901 Solution for Nebulization	—	COMPLETED	2022-12-02	NCT04903730
Chong Kun Dang Pharmaceutical	D064+D701	—	COMPLETED	2022-11-15	NCT05540912
E-Star BioTech, LLC	MANP	—	COMPLETED	2022-10-31	NCT05247528
Vigonvita Life Sciences	TPN171H single dose	—	COMPLETED	2022-10-25	NCT05208814
Boryung Pharmaceutical Co., Ltd	BR1018-1	—	COMPLETED	2022-10-17	NCT05460364
AstraZeneca	baxdrostat	—	COMPLETED	2022-09-20	NCT05966324
Aadi Bioscience, Inc.	nab-sirolimus	—	COMPLETED	2022-08-16	NCT02587325
Boryung Pharmaceutical Co., Ltd	BR1017-1	—	COMPLETED	2022-06-04	NCT05372380
Attgeno AB	PDNO	—	COMPLETED	2022-05-25	NCT04891354
Bayer	BAY1237592	—	COMPLETED	2022-04-24	NCT03754660
Alnylam Pharmaceuticals	ALN-AGT01	—	COMPLETED	2022-04-20	NCT03934307
AstraZeneca	baxdrostat	—	COMPLETED	2022-04-15	NCT05961397
Pfizer	Prazosin HCl 2mg	—	COMPLETED	2022-02-15	NCT04967443
Vigonvita Life Sciences	TPN171H	—	COMPLETED	2022-02-06	NCT05185011
AstraZeneca	baxdrostat	—	COMPLETED	2022-01-15	NCT05961384
Merck	Frespaciguat	—	COMPLETED	2022-01-12	NCT04370873
HK inno.N Corporation	Telmione plus 80/12.5mg	—	COMPLETED	2021-10-31	NCT05040880
Boryung Pharmaceutical Co., Ltd	BR1015-1	—	COMPLETED	2021-10-22	NCT05097794
Theravance Biopharma	Ampreloxetine	—	COMPLETED	2021-08-19	NCT04200573
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	GB002	—	COMPLETED	2021-05-05	NCT03926793
AstraZeneca	CIN-107	—	COMPLETED	2021-04-30	NCT05470725
Gmax Biopharm Australia Pty Ltd.	GMA301 Injection	—	COMPLETED	2021-03-19	NCT04505137
Theravance Biopharma	Ampreloxetine <Dose A>	—	COMPLETED	2021-03-13	NCT04688632
Addpharma Inc.	AD-2101	—	COMPLETED	2021-01-20	NCT04600284
AstraZeneca	Metformin	—	COMPLETED	2020-12-12	NCT05526690
Merck	Frespaciguat	—	COMPLETED	2020-12-11	NCT03744637
Vigonvita Life Sciences	TPN171H	—	COMPLETED	2020-10-14	NCT05948644
Jiangsu HengRui Medicine Co., Ltd.	SHR0532	—	COMPLETED	2020-09-03	NCT03971929
AstraZeneca	baxdrostat (formerly CIN-107) oral solution	—	COMPLETED	2020-04-29	NCT05963009
Hanlim Pharm. Co., Ltd.	Twynsta	—	COMPLETED	2020-04-28	NCT04667624

Novel Hypertension Drugs by Company (New molecular entities)

2 companies have an FDA-approved novel drug for Hypertension.

AstraZeneca 1 drug

IDORSIA 1 drug

Reformulations (75 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.